Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exogen Acquisition Gives Smith & Nephew Ultrasound Fracture Product

This article was originally published in The Gray Sheet

Executive Summary

Smith & Nephew will add a non-invasive ultrasound fracture healing system to its orthopedic product line through the purchase of Piscataway, New Jersey-based Exogen. A definitive agreement for the $68 mil. cash deal was announced July 26.

You may also be interested in...



Smith & Nephew Exogen 2000 Labeling For Non-Union Fracture Approved

Smith & Nephew will employ its 300-person direct sales force to promote an expanded indication for the Exogen 2000 low-intensity pulsed ultrasound device for treatment of non-union bone fractures, a market valued at roughly $110 mil.

Smith & Nephew Exogen 2000 Labeling For Non-Union Fracture Approved

Smith & Nephew will employ its 300-person direct sales force to promote an expanded indication for the Exogen 2000 low-intensity pulsed ultrasound device for treatment of non-union bone fractures, a market valued at roughly $110 mil.

Smith & Nephew

Firm's recently divested bracing and support systems division, including DonJoy and ProCare orthopedics product lines, changes its name to dj Orthopedics, LLC. Sold April 30 to Chase Capital Partners, Fairfield Chase Medical Partners and senior management for approximately $202 mil., the business will focus on expanding product lines and identifying growth opportunities, including collaborations with other firms (1"The Gray Sheet" May 10, p. 23)

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel